iQSTEL increases authorized common stock to 26 million shares

iQSTEL Inc. has significantly increased its authorized common stock from 3.75 million to 26 million shares, effective after September 15, 2025, without disclosing the purpose, which could signal future dilution given the stock's over 75% year-to-date decline. This development occurs as the company reports strong preliminary H1 2025 revenue of $128.8 million, targets a $400 million annual revenue run rate by Q3, and reaffirms ambitious goals including $1 billion in revenue by 2027 and $15 million EBITDA by 2026, partly driven by strategic acquisitions financed with debt and preferred shares. The lack of clarity on the share increase's intent creates a notable point of concern amidst its aggressive growth and operational performance claims.

Analysis

iQSTEL Inc. (IQST) presents a conflicting profile for investors, characterized by aggressive operational growth juxtaposed with significant potential for shareholder dilution. The company has increased its authorized common stock nearly seven-fold, from 3.75 million to 26 million shares, a move made without a stated purpose and against the backdrop of a stock that has declined over 75% year-to-date. This action raises concerns about a potential future equity offering at depressed prices. Conversely, IQST reported strong preliminary revenue of $128.8 million for H1 2025 and is on track to achieve a $400 million annual revenue run rate by Q3 2025, ahead of schedule. Management has reaffirmed ambitious targets, including $1 billion in revenue by 2027 and $15 million in EBITDA by 2026, supported by a strategy to acquire companies using debt and preferred shares. While operating subsidiaries are reportedly generating positive EBITDA and net income, and an external analysis indicates a 'FAIR' financial health score with moderate debt, the lack of transparency regarding the substantial share authorization creates a material uncertainty that weighs against the positive operational announcements and new AI-related commercial agreements.

Key Decisions for Investors

• Investors should weigh the company's strong reported revenue growth and ambitious targets against the substantial risk of shareholder dilution implied by the massive increase in authorized common stock, particularly given the stock's severe year-to-date underperformance.
• It is critical to monitor the company's future financing activities for its planned acquisitions, specifically whether it adheres to its stated plan of using debt and preferred shares or utilizes the newly authorized common stock, which would be a key negative indicator.
• While top-line growth is accelerating, focus should be on the company's ability to translate this into consolidated profitability and meet its $15 million EBITDA target by 2026, as execution on this front remains a primary catalyst for long-term value creation.